Search results for "multiple sclerosis"

showing 10 items of 630 documents

β1-Integrin– and K(V)1.3 channel–dependent signaling stimulates glutamate release from Th17 cells

2020

Although the impact of Th17 cells on autoimmunity is undisputable, their pathogenic effector mechanism is still enigmatic. We discovered soluble N-ethylmaleimide–sensitive factor attachment receptor (SNARE) complex proteins in Th17 cells that enable a vesicular glutamate release pathway that induces local intracytoplasmic calcium release and subsequent damage in neurons. This pathway is glutamine dependent and triggered by binding of β1-integrin to vascular cell adhesion molecule 1 (VCAM-1) on neurons in the inflammatory context. Glutamate secretion could be blocked by inhibiting either glutaminase or K(V)1.3 channels, which are known to be linked to integrin expression and highly expressed…

0301 basic medicineMultiple SclerosisGlutamic AcidVascular Cell Adhesion Molecule-1Cell Communication03 medical and health sciencesMice0302 clinical medicineAnimalsHumansChannel blockerReceptorNeuroinflammationMice KnockoutKv1.3 Potassium ChannelGlutamate secretionChemistryGlutaminaseCell adhesion moleculeIntegrin beta1Glutamate receptorGeneral MedicineCell biologyGlutamine030104 developmental biology030220 oncology & carcinogenesisTh17 CellsSNARE ProteinsResearch ArticleSignal Transduction
researchProduct

Oleanane-type glycosides from the roots of Weigela florida “rumba” and evaluation of their antibody recognition

2018

Three triterpene glycosides were isolated from the roots of Weigela florida "rumba" (Bunge) A. DC.: two previously undescribed 3-O-β-d-xylopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→4)]-β-d-xylopyranosyl-(1→4)-β-d-xylopyranosyl-(1→3)-α-L-rhamnopyranosyl-(1→2)-α-l-arabinopyranosyloleanolic acid (1) and 3-O-β-d-xylopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-xylopyranosyl-(1→4)-β-d-xylopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyloleanolic acid (2), and one isolated for the first time from a natural source 3-O-β-d-xylopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-l-arabinopyranosyloleanolic acid (3). Their structures were elucidated mainly by 2D NMR spectroscopic analysis (COSY, …

0301 basic medicineMultiple SclerosisStereochemistryEnzyme-Linked Immunosorbent AssayCaprifoliaceaePlant Roots01 natural sciences03 medical and health scienceschemistry.chemical_compoundTriterpeneDrug DiscoveryHumansGlycosidesOleanolic AcidCaprifoliaceaeOleanolic acidOleananePharmacologychemistry.chemical_classificationMolecular Structurebiology010405 organic chemistryGlycosideGeneral Medicinebiology.organism_classification0104 chemical sciences030104 developmental biologyImmunoglobulin MchemistryImmunoglobulin Mbiology.proteinAntibodyTwo-dimensional nuclear magnetic resonance spectroscopyFitoterapia
researchProduct

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning

2020

Genome-wide association studies (GWAS) identify genetic variants associated with traits or diseases. GWAS never directly link variants to regulatory mechanisms. Instead, the functional annotation of variants is typically inferred by post hoc analyses. A specific class of deep learning-based methods allows for the prediction of regulatory effects per variant on several cell type-specific chromatin features. We here describe “DeepWAS”, a new approach that integrates these regulatory effect predictions of single variants into a multivariate GWAS setting. Thereby, single variants associated with a trait or disease are directly coupled to their impact on a chromatin feature in a cell type. Up to…

0301 basic medicineMultivariate analysisGene ExpressionGenome-wide association studyBiochemistry0302 clinical medicineGenotypeMedicine and Health SciencesBiology (General)0303 health sciencesDNA methylationEcologyChromosome BiologyNeurodegenerative DiseasesGenomicsChromatinChromatinNucleic acidsNeurologyComputational Theory and MathematicsModeling and SimulationDNA methylationTraitEpigeneticsDNA modificationFunction and Dysfunction of the Nervous SystemChromatin modificationResearch ArticleMultiple SclerosisQH301-705.5Quantitative Trait LociImmunologySingle-nucleotide polymorphismComputational biologyBiologyQuantitative trait locusPolymorphism Single NucleotideAutoimmune DiseasesMolecular Genetics03 medical and health sciencesCellular and Molecular NeuroscienceDeep LearningGenome-Wide Association StudiesGeneticsHumansGeneMolecular BiologyGenetic Association StudiesEcology Evolution Behavior and Systematics030304 developmental biologyGenetic associationBiology and Life SciencesComputational BiologyHuman GeneticsCell BiologyDNAGenome AnalysisDemyelinating Disorders030104 developmental biologyGenetic LociMultivariate AnalysisClinical ImmunologyClinical Medicine030217 neurology & neurosurgeryGenome-Wide Association StudyPLOS Computational Biology
researchProduct

2018

Evoked potentials (EPs) are well established in clinical practice for diagnosis and prognosis in multiple sclerosis (MS). However, their value is limited to the assessment of their respective functional systems. Here, we used transcranial magnetic stimulation (TMS) coupled with electroencephalography (TMS-EEG) to investigate cortical excitability and spatiotemporal dynamics of TMS-evoked neural activity in MS patients. Thirteen patients with early relapsing-remitting MS (RRMS) with a median Expanded Disability Status Scale (EDSS) of 1.0 (range 0-2.5) and 16 age- and gender-matched healthy controls received single-pulse TMS of left and right primary motor cortex (L-M1 and R-M1), respectively…

0301 basic medicineN100Expanded Disability Status Scalemedicine.diagnostic_testbusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.medical_treatmentArea under the curveStimulationElectroencephalographymedicine.diseaseTranscranial magnetic stimulation03 medical and health sciences030104 developmental biology0302 clinical medicinemedicinePrimary motor cortexbusinessNeuroscience030217 neurology & neurosurgeryFrontiers in Neuroscience
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

Semaphorins in Adult Nervous System Plasticity and Disease

2021

Semaphorins, originally discovered as guidance cues for developing axons, are involved in many processes that shape the nervous system during development, from neuronal proliferation and migration to neuritogenesis and synapse formation. Interestingly, the expression of many Semaphorins persists after development. For instance, Semaphorin 3A is a component of perineuronal nets, the extracellular matrix structures enwrapping certain types of neurons in the adult CNS, which contribute to the closure of the critical period for plasticity. Semaphorin 3G and 4C play a crucial role in the control of adult hippocampal connectivity and memory processes, and Semaphorin 5A and 7A regulate adult neuro…

0301 basic medicineNervous systemsemaphorinsanimal structuresautismNeurosciences. Biological psychiatry. NeuropsychiatryReviewHippocampal formationBiologymultiple sclerosisExtracellular matrix03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSemaphorinNeuroplasticitymedicineMultiple sclerosisPerineuronal netNeurogenesisCell Biologymedicine.diseaseschizophrenia030104 developmental biologymedicine.anatomical_structurenervous systemplasticityembryonic structuresAlzheimer’s disease; autism; epilepsy; multiple sclerosis; perineuronal net; plasticity; schizophrenia; semaphorinsepilepsysense organsperineuronal netbiological phenomena cell phenomena and immunityNeuroscienceAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceRC321-571
researchProduct

Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs

2018

Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by a galactosidase A (a-gal A) deficiency. Central nervous system involvement and chronic white matter lesions are observed in both FD and multiple sclerosis (MS), which can confound the differential diagnosis. We analyzed the GLA gene, which encodes a-gal A, in 86 patients with clinical and neuroradiological findings consistent with MS to determine whether they had FD. We identified four women initially diagnosed with MS who had GLA mutations associated with FD. Our results indicate that family history besides neurological findings should be evaluated in patients with an uncertain diagnosis of MS. Also the involv…

0301 basic medicineNeurological signsPathologymedicine.medical_specialtyCentral nervous systemmultiple sclerosis03 medical and health sciences0302 clinical medicineα galactosidase aMedicinemisdiagnosisFamily historyfabry diseasebusiness.industryMultiple sclerosismedicine.diseaseFabry diseaseResearch Paper: PathologyHyperintensity3. Good health030104 developmental biologymedicine.anatomical_structureOncologyMisdiagnosiDifferential diagnosisbusiness030217 neurology & neurosurgeryOncotarget
researchProduct

Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.

2018

Background and objectives: Percentages of blood CD19 + CD5 + B cells and CD8 + perforin + T lymphocytes can predict response to Interferon (IFN)-beta treatment in relapsing-remitting multiple sclerosis (RRMS) patients. We aimed to standardize their detection in a multicenter study, prior to their implementation in clinical practice. Methods: Fourteen hospitals participated in the study. A reference centre was established for comparison studies. Peripheral blood cells of 105 untreated RRMS patients were studied. Every sample was analyzed in duplicate in the participating centre and in the reference one by flow cytometry. When needed, participating centres corrected fluorescence compensations…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyMultiple SclerosisIntraclass correlationConcordanceT cellClinical BiochemistryImmunologyBiochemistrySpearman's rank correlation coefficientMultiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMulticenter Studies as TopicFlow cytometryB cellbusiness.industryMultiple sclerosisBiochemistry (medical)General MedicineInterferon-betaMiddle Agedmedicine.diseaseFlow Cytometry030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisFemaleCD5businessCD8BiomarkersClinica chimica acta; international journal of clinical chemistry
researchProduct

Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer’s Disease and Chronic Progressive Multiple Sclerosis: A Review

2020

Background: Reducing the burden of beta-amyloid accumulation and toxic autoimmunity-related proteins, one of the recognized pathophysiological markers of chronic and common neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS), may be a valid alternative therapy to reduce their accumulation in the brain and thus reduce the progression of these disorders. The objective of this review was to evaluate the efficacy of plasmapheresis (PP) in AD and chronic progressive MS patients (in terms of improving clinical symptoms) and to analyze its safety and protocols. Methods: Articles related to this topic and published without time limitations in the Medline, and C…

0301 basic medicineOncologymedicine.medical_specialtyAmyloid betamedicine.medical_treatmentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441DiseaseReviewlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineVerbal fluency testDementiamagnetic resonance imagingauto-immunityalbuminbiologybusiness.industryMultiple sclerosislcsh:Rmedicine.diseasePathophysiologyamyloid beta030104 developmental biologyplasmapheresisToxicitybiology.proteinMolecular MedicinePlasmapheresisbusiness030217 neurology & neurosurgerydementiaPharmaceuticals
researchProduct

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct